Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Rivaroxaban Oral Suspension in Healthy Males
NCT02367027Phase 1Completed
- Sponsor
- Bayer
- Start
- Feb 2015
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rivaroxaban in thromboembolism (4 arms), sponsored by Bayer. Primary endpoints: Area Under the Plasma Concentration-Time Curve, Dose-Normalized Area Under the Curve and 2 more. Started Feb 2015; status: completed.
02
Drugs
rivaroxaban
03
Conditions
thromboembolism
Beyond the preview
Go deeper on NCT02367027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02367027.